Tiếp theo

Tự chạy

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

2 Lượt xem • 07/14/23
Đăng lại
Nhúng
administrator
administrator
Người đăng ký
0

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…

Cho xem nhiều hơn
0 Bình luận sort Sắp xếp theo
Bình luận trên Facebook

Tiếp theo

Tự chạy